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Measuring antibiotic use in children: piecing together the 
puzzle
In The Lancet Global Health, Emily White Johansson 
and colleagues present new estimates of the trends 
in reported antibiotic use for sick children under the 
age of 5 years in 73 low-income and middle-income 
countries (LMICs).1 Using data from Demographic and 
Health Surveys and Multiple Indicator Cluster Surveys, 
the group identifies an increasing reported antibiotic 
use between 2005 and 2017 in LMICs overall. The 
observed increase appears to be driven by low-income 
countries moving to from a 36·8% (uncertainty interval 
[UI] 28·8–44·7) reported antibiotic use among sick 
children under the age of 5 years in 2005 to 43·1% 
(33·2–50·5) in 2017. Disaggregating the model outputs 
by WHO regions, estimates for the African region and 
South-east Asia have the greatest precision since most 
of the countries regularly participate in Demographic 
and Health Surveys and Multiple Indicator Cluster 
Surveys. In both WHO regions, antibiotic use continues 
to be below the overall LMIC average, despite the 
increases observed.
Generating reliable estimates of antibiotic use in 
children remains a major struggle, particularly for LMICs. 
In general, three main data sources have been used 
to provide insights into the use of antibiotics in this 
population: hospital-based assessments, in particular 
point-prevalence surveys; sales data; and cross-sectional 
survey data, including the Demographic and Health 
Surveys and Multiple Indicator Cluster Surveys.2–4 
Hospital-based assessments have limitations for 
describing population-level antibiotic use, since most 
antibiotics are prescribed, obtained, and used outside of 
major hospitals. Sales data can provide insights into the 
volume of use, but are difficult to collect and interpret, 
generally not publicly available, and cannot support 
inferences about individual exposure.3
Cross-sectional surveys appear to provide the most 
reliable data on average exposure at the population 
level. Nevertheless, such surveys are subject to a number 
of important biases, in particular when relying on data 
recall of surveyed participants. Recall of antibiotic 
receipt has been shown to be reasonable in France, 
with 73% of actually dispensed antibiotics reported as 
such by surveyed adults when matched to electronic 
dispensing records.5 However, that study took place 
in a high-income country with relatively low expected 
rates of over-the-counter antibiotic dispensing. Even 
in this setting, only about 40% of participating adults 
could recall the type of antibiotic obtained. Considering 
much higher exposure to antibiotics in many LMICs, 
and also that most caregivers have to report on multiple 
children and illness episodes, substantial recall biases in 
Demographic and Health Surveys and Multiple Indicator 
Cluster Surveys seem likely.
In a prospective birth cohort study that took place in 
eight LMICs, an average use of 4·9 antibiotic courses 
per child per year was found.6 Wide variation was 
observed between settings, but with the exception of 
the Brazilian and South African subcohorts, half of the 
children had been prescribed at least one antibiotic 
course by half a year of age. Cumulative exposure in 
the first 2 years ranged between less than 1 dose in 
Brazil and South Africa to more than 10 doses per 
child-year in Bangladesh and Pakistan.6 The overall 
heterogeneity in antibiotic consumption across 
countries documented in the literature is remarkable4,6 
and should be kept in mind when interpreting global or 
regional estimates.
There are ongoing discussions about the best 
approach towards balancing access to antibiotics and 
excess use in LMICs.7 What is becoming clearer is that 
more antibiotic use for sick children under the age of 
5 years in LMICs is not simply better, but that instead 
use should be as targeted as possible. Characterising 
40% antibiotic use in LMICs as low could therefore be 
misleading. In many LMIC population surveys such as 
Demographic and Health Surveys and Multiple Indicator 
Cluster Surveys, morbidity episodes involving fever, 
diarrhoea, or cough are reported for one third or more 
of all children under the age of 5 years over a 2-week 
recall period.4 Based on these estimates, children will 
have had about 40 illness episodes on average by 
their fifth birthday, resulting in 16 antibiotic courses 
if 40% of these episodes are treated with antibiotics. 
Given that a large share of antibiotic prescriptions has 
been found unnecessary in a recent LMIC-based study,8 
40% antibiotic use is likely much more than what is 
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really needed for the treatment of most fever, diarrhoea, 
and respiratory infections.
So how do we go about evaluating the quality 
of antibiotic use for young children in LMICs? 
One approach could be to investigate the relative 
proportions of antibiotic prescriptions or use based on 
antibiotic stewardship groups defined by WHO (Access, 
Watch, Reserve [AWaRe] classification) for the Essential 
Medicines List.9 Although quality of antibiotic use is 
difficult to assess, monitoring is essential to complement 
more quantitative measurements. Increasing access to 
antibiotics, as reported by Johansson and colleagues1 
and others,4 could result in excessive and ultimately 
inequitable use, which excludes children most at 
need of antibiotic treatment. Strengthening granular, 
linked-up, and high-quality surveillance of antibiotic 
consumption by young children through improvement 
of current tools and through use of innovative methods 
of data collection will inform approaches to safeguard 
this limited resource for those who most need it in the 
future.
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